Tabula Rasa HealthCare (NASDAQ:TRHC) Lifted to “Buy” at BidaskClub

BidaskClub upgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a hold rating to a buy rating in a research note issued to investors on Friday, BidAskClub reports.

A number of other research analysts have also commented on TRHC. TheStreet lowered Twin Disc from a b- rating to a c+ rating in a research note on Tuesday, June 11th. Guggenheim initiated coverage on Patterson Companies in a research note on Wednesday, April 17th. They issued a neutral rating and a $23.00 target price for the company. Cantor Fitzgerald initiated coverage on CytomX Therapeutics in a research note on Monday, May 13th. They issued an overweight rating and a $21.00 target price for the company. Piper Jaffray Companies upped their target price on Beigene to $180.00 and gave the company an overweight rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research lowered GENEL ENERGY PL/ADR from a hold rating to a sell rating in a research note on Thursday, July 4th. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $82.12.

Shares of NASDAQ TRHC opened at $54.95 on Friday. The company has a fifty day moving average price of $48.66. The company has a quick ratio of 1.73, a current ratio of 1.80 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 161.62 and a beta of 1.63. Tabula Rasa HealthCare has a one year low of $40.86 and a one year high of $91.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, meeting analysts’ consensus estimates of ($0.14). The business had revenue of $60.96 million during the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. On average, equities analysts anticipate that Tabula Rasa HealthCare will post -0.55 EPS for the current year.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,270 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $48.50, for a total value of $388,000.00. The disclosure for this sale can be found here. Insiders have sold 50,270 shares of company stock valued at $2,457,654 over the last quarter. Corporate insiders own 11.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in shares of Tabula Rasa HealthCare by 1.6% during the fourth quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock worth $165,831,000 after purchasing an additional 40,174 shares during the last quarter. Polar Capital LLP bought a new stake in shares of Tabula Rasa HealthCare during the fourth quarter worth $3,953,000. Nicholas Company Inc. grew its holdings in shares of Tabula Rasa HealthCare by 6.5% during the fourth quarter. Nicholas Company Inc. now owns 77,485 shares of the company’s stock worth $4,940,000 after purchasing an additional 4,750 shares during the last quarter. Summit Creek Advisors LLC bought a new stake in shares of Tabula Rasa HealthCare during the first quarter worth $2,885,000. Finally, Advisor Group Inc. grew its holdings in shares of Tabula Rasa HealthCare by 547.9% during the fourth quarter. Advisor Group Inc. now owns 12,557 shares of the company’s stock worth $801,000 after purchasing an additional 10,619 shares during the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: Different Types of Derivatives

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit